MedTrace Logo

PET Study in Parkinson's Disease Patients

NCT01527695 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-01-31

No results posted yet for this study

Summary

This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be randomised in the study to allow for 20 patients to complete this study.The study will evaluate the effect of 8 weeks treatment with AZD3241 on microglia activation as measured via PET examinations.

Conditions

Interventions

DRUG

ER tablet 25 mg AZD3241

2 tablets twice daily for Day 1

DRUG

ER tablet 100 mg AZD3241

1-6 tablets twice daily from Day 2 until Day 56±3 days

DRUG

Placebo for AZD3241 25 mg

2 tablets twice daily for Day 1

DRUG

Placebo for AZD3241 100 mg

1-6 tablets twice daily from Day 2 until Day 56±3 days

Sponsors & Collaborators

Principal Investigators

  • Per Svenningsson, MD, PHD · Karolinska University Hospital

  • Bjorn Paulsson, MD · AstraZeneca Medical Science Director

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01527695 on ClinicalTrials.gov